"Triple-H" therapy for cerebral vasospasm following subarachnoid hemorrhage

Kendall H Lee, Timothy Lukovits, Jonathan A. Friedman

Research output: Contribution to journalArticle

104 Citations (Scopus)

Abstract

The combination of induced hypertension, hypervolemia, and hemodilution (triple-H therapy) is often utilized to prevent and treat cerebral vasospasm after aneurysmal subarachnoid hemorrhage (SAH). Although this paradigm has gained widespread acceptance over the past 20 years, the efficacy of triple-H therapy and its precise role in the management of the acute phase of SAH remains uncertain. In addition, triple-H therapy may carry significant medical morbidity, including pulmonary edema, myocardial ischemia, hyponatremia, renal medullary washout, indwelling catheter-related complications, cerebral hemorrhage, and cerebral edema. This review examines the evidence underlying the implementation of triple-H therapy, and makes practical recommendations for the use of this therapy in patients with aneurysmal SAH.

Original languageEnglish (US)
Pages (from-to)68-76
Number of pages9
JournalNeurocritical Care
Volume4
Issue number1
DOIs
StatePublished - Feb 2006
Externally publishedYes

Fingerprint

Intracranial Vasospasm
Subarachnoid Hemorrhage
Therapeutics
Hemodilution
Indwelling Catheters
Hyponatremia
Brain Edema
Cerebral Hemorrhage
Pulmonary Edema
Myocardial Ischemia
Hypertension
Morbidity
Kidney

Keywords

  • Aneurysm
  • Cerebrovascular disease
  • Subarachnoid hemorrhage
  • Triple-H therapy
  • Vasospasm

ASJC Scopus subject areas

  • Clinical Neurology
  • Critical Care and Intensive Care Medicine

Cite this

"Triple-H" therapy for cerebral vasospasm following subarachnoid hemorrhage. / Lee, Kendall H; Lukovits, Timothy; Friedman, Jonathan A.

In: Neurocritical Care, Vol. 4, No. 1, 02.2006, p. 68-76.

Research output: Contribution to journalArticle

Lee, Kendall H ; Lukovits, Timothy ; Friedman, Jonathan A. / "Triple-H" therapy for cerebral vasospasm following subarachnoid hemorrhage. In: Neurocritical Care. 2006 ; Vol. 4, No. 1. pp. 68-76.
@article{c44ea36a0a024dba855d220fb38f5a84,
title = "{"}Triple-H{"} therapy for cerebral vasospasm following subarachnoid hemorrhage",
abstract = "The combination of induced hypertension, hypervolemia, and hemodilution (triple-H therapy) is often utilized to prevent and treat cerebral vasospasm after aneurysmal subarachnoid hemorrhage (SAH). Although this paradigm has gained widespread acceptance over the past 20 years, the efficacy of triple-H therapy and its precise role in the management of the acute phase of SAH remains uncertain. In addition, triple-H therapy may carry significant medical morbidity, including pulmonary edema, myocardial ischemia, hyponatremia, renal medullary washout, indwelling catheter-related complications, cerebral hemorrhage, and cerebral edema. This review examines the evidence underlying the implementation of triple-H therapy, and makes practical recommendations for the use of this therapy in patients with aneurysmal SAH.",
keywords = "Aneurysm, Cerebrovascular disease, Subarachnoid hemorrhage, Triple-H therapy, Vasospasm",
author = "Lee, {Kendall H} and Timothy Lukovits and Friedman, {Jonathan A.}",
year = "2006",
month = "2",
doi = "10.1385/Neurocrit. Care 2006;04:68-76",
language = "English (US)",
volume = "4",
pages = "68--76",
journal = "Neurocritical Care",
issn = "1541-6933",
publisher = "Humana Press",
number = "1",

}

TY - JOUR

T1 - "Triple-H" therapy for cerebral vasospasm following subarachnoid hemorrhage

AU - Lee, Kendall H

AU - Lukovits, Timothy

AU - Friedman, Jonathan A.

PY - 2006/2

Y1 - 2006/2

N2 - The combination of induced hypertension, hypervolemia, and hemodilution (triple-H therapy) is often utilized to prevent and treat cerebral vasospasm after aneurysmal subarachnoid hemorrhage (SAH). Although this paradigm has gained widespread acceptance over the past 20 years, the efficacy of triple-H therapy and its precise role in the management of the acute phase of SAH remains uncertain. In addition, triple-H therapy may carry significant medical morbidity, including pulmonary edema, myocardial ischemia, hyponatremia, renal medullary washout, indwelling catheter-related complications, cerebral hemorrhage, and cerebral edema. This review examines the evidence underlying the implementation of triple-H therapy, and makes practical recommendations for the use of this therapy in patients with aneurysmal SAH.

AB - The combination of induced hypertension, hypervolemia, and hemodilution (triple-H therapy) is often utilized to prevent and treat cerebral vasospasm after aneurysmal subarachnoid hemorrhage (SAH). Although this paradigm has gained widespread acceptance over the past 20 years, the efficacy of triple-H therapy and its precise role in the management of the acute phase of SAH remains uncertain. In addition, triple-H therapy may carry significant medical morbidity, including pulmonary edema, myocardial ischemia, hyponatremia, renal medullary washout, indwelling catheter-related complications, cerebral hemorrhage, and cerebral edema. This review examines the evidence underlying the implementation of triple-H therapy, and makes practical recommendations for the use of this therapy in patients with aneurysmal SAH.

KW - Aneurysm

KW - Cerebrovascular disease

KW - Subarachnoid hemorrhage

KW - Triple-H therapy

KW - Vasospasm

UR - http://www.scopus.com/inward/record.url?scp=33144480915&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33144480915&partnerID=8YFLogxK

U2 - 10.1385/Neurocrit. Care 2006;04:68-76

DO - 10.1385/Neurocrit. Care 2006;04:68-76

M3 - Article

VL - 4

SP - 68

EP - 76

JO - Neurocritical Care

JF - Neurocritical Care

SN - 1541-6933

IS - 1

ER -